Veterinary Packaging Shijiazhuang Xinfuda Medical Packaging Co., Ltd.

E-MAIL: [email protected]

FDA-DMF Query
Home > News

ICH Q1D BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS

Jul 22 , 2025

1. INTRODUCTION

 

1.1 Objectives of the Guideline This guideline is intended to address recommendations on the application of bracketing and matrixing to stability studies conducted in accordance with principles outlined in the ICH Q1A(R) Harmonised Tripartite guideline on Stability Testing of New Drug Substances and Products (hereafter referred to as the parent guideline).

 

1.2 Background The parent guideline notes that the use of matrixing and bracketing can be applied, if justified, to the testing of new drug substances and products, but provides no further guidance on the subject.

 

1.3 Scope of the Guideline This document provides guidance on bracketing and matrixing study designs. Specific principles are defined in this guideline for situations in which bracketing or matrixing can be applied. Sample designs are provided for illustrative purposes, and should not be considered the only, or the most appropriate, designs in all cases.

 

2. GUIDELINES

 

2.1 General A full study design is one in which samples for every combination of all design factors are tested at all time points. A reduced design is one in which samples for every factor combination are not all tested at all time points. A reduced design can be a suitable alternative to a full design when multiple design factors are involved. Any reduced design should have the ability to adequately predict the retest period or shelf life. Before a reduced design is considered, certain assumptions should be assessed and justified. The potential risk should be considered of establishing a shorter retest period or shelf life than could be derived from a full design due to the reduced amount of data collected.

 

During the course of a reduced design study, a change to full testing or to a less reduced design can be considered if a justification is provided and the principles of full designs and reduced designs are followed. However, proper adjustments should be made to the statistical analysis, where applicable, to account for the increase in sample size as a result of the change. Once the design is changed, full testing or less reduced testing should be carried out through the remaining time points of the stability study.

 

Source: ICH, Pls check the follow

Q1D Guideline.pdf


Why Silica Gel Desiccant Bottle Packaging Is Essential in the Pharmaceutical Industry

desiccant bottle with silica gel

 

Why Silica Gel Desiccant Bottle Packaging Is Essential in the Pharmaceutical Industry

50ml desiccant bottle with CRC


Back to List
Share:
HOT PRODUCTS
twitter facebook youtube linkedin pinterest

Copyright © Shijiazhuang Xinfuda Medical Packaging Co., Ltd. All Rights

Reserved Powered by    

MAKE AN ENQUIRY

verification

wechat